Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neuraxis, INCNRXS · Entity 6994 | CMO, SVP Science & Tech | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neuraxis, INC
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 199,106 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 199,106 · Balance 199,106 F1: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. |
| Stock OptionsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-24 · Conversion · Disposed 337,204 · Balance 0 F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. |
| RSUSEC Table II · derivative / convertible security | Direct | 337,204 |
Reported balance
After 2026-08-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-24 · Grant · Acquired 337,204 · Balance 337,204 F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. |
| RSUSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-24 · Conversion · Disposed 337,204 · Balance 0 F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs.
F2: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 26, 2026 21:30 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionRSU · Derivative | 337,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 4 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 337,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:30 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 337,204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 3 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,204 Underlying: Common Stock · 337,204 shares Expires not disclosed F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:30 UTC | Neuraxis, INC NRXS · Entity 6994 | ConversionStock Options · Derivative | 337,204 | $6.94 | $2,340,195.76 |
DisclosureSEC source: 0001493152-26-040276 · ownership.xml · derivative · entry 2 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 337,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.exercise_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. F2 · derivative.expiration_date: Following approval by the Company's Board of Directors and stockholders of the cancellation of stock options issued under the 2017 Innovative Health Solutions, Inc. Stock Compensation Plan and the grant of an equivalent number of RSUs under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan, the reporting person's stock options were canceled in exchange for an equivalent number of RSUs, which vested immediately upon grant. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 21:30 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantCommon Stock | 199,106 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-040276 · ownership.xml · nonDerivative · entry 1 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,106 F1 · shares: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. F1 · price: Reference is made to the 337,204 restricted stock units ("RSUs") granted and vested to the Reporting Person under the NeurAxis, Inc. 2022 Omnibus Securities and Incentive Plan as discussed below, of which 138,098 shares were withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of RSUs. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 22:36 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 133,341 | $6.28 | $837,381.48 |
DisclosureSEC source: 0001493152-26-038829 · ownership.xml · derivative · entry 1 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,341 Underlying: Common Stock · 133,341 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Read SEC document |
| January 22, 2026 Filed Mar 2, 2026 21:10 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 47,569 | $4.63 | $220,244.47 |
DisclosureSEC source: 0001493152-26-008545 · ownership.xml · derivative · entry 1 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,569 Underlying: Common Stock · 47,569 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Read SEC document |
| March 04, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 30,000 | $2.18 | $65,400.00 |
DisclosureSEC source: 0001641172-25-027022 · ownership.xml · derivative · entry 2 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F2 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F2 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F2 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. Read SEC document |
| March 04, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 10,000 | $2.18 | $21,800.00 |
DisclosureSEC source: 0001641172-25-027022 · ownership.xml · derivative · entry 1 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. F1 · derivative.exercise_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. F1 · derivative.expiration_date: These shares of common stock are restricted stock units (RSUs) granted to the reporting person as bonus under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs will vest in full at the end of 36 months. Read SEC document |
| January 03, 2025 Filed Sep 10, 2025 10:32 UTC | Neuraxis, INC NRXS · Entity 6994 | GrantRSU · Derivative | 35,000 | $2.42 | $84,700.00 |
DisclosureSEC source: 0001641172-25-027022 · ownership.xml · derivative · entry 3 Miranda Adrian · CIK 0001992525 · CMO, SVP Science & Tech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F3 · derivative.exercise_price: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F3 · derivative.exercise_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. F3 · derivative.expiration_date: These shares of common stock are RSUs granted to the reporting person under the Long-Term Incentive Plan. The RSUs will vest in full at the end of 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.